Study title:
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-
Long title:
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-
Date receipt dossier:
1 Mar 2024
EudraCT number:
2023-506259-97
Pharmaceutical study code:
JNJ-90009530
Company / Sponsor:
Janssen-Cilag International NV
Phase:
Ib
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
Relapsed or refractory B cell non-Hodgkin lymphoma
Therapeutic approach:
Immunotherapy
Genetic modification:
CD20 CAR
Method of transfer of nucleic acid of interest:
Lentiviral vector
Administered biological material:
Autologous T cells transduced with lentiviral vectors expressing CD20-CAR
Route of administration:
Intravenous
Locations in Belgium:
UZ Gent
Type of procedure:
Contained use only
Current status:
Authorized